Posts

Henlius to Showcase 12 Research Presentations at ESMO 2026, Including U.S. Bridging Study of Serplulimab and PoC of PD-L1 ADC HLX43 in Gastric Cancer (Summary Highlights)

on

Labcorp Launches FDA-Approved Companion Diagnostic for KEYTRUDA in Platinum-Resistant Ovarian Cancer

on

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

on

Merck & Co. Announces Keytruda Achieves First Overall Survival Benefit in Resistant Ovarian Cancer

on

Moderna Unveils Promising mRNA-4359 Cancer Antigen Therapy Data in Melanoma Ahead of ESMO 2025

on

Recent Trends in Biomarker Testing for NSCLC: Maximizing Real-World Survival

on

BioNTech and BMS Announce First Global Data for PD-L1xVEGF Bispecific in Small Cell Lung Cancer, Set Phase 3 Dose

on

Bristol Myers Squibb Commits Up to $11B+ in Major BioNTech Solid Tumor Bispecific Antibody Deal

on

Bicara’s Ficerafusp Alfa Shows 46% 2-Year Survival Rate for Head and Neck Cancer Subset at ASCO 2025

on

Bristol Myers Squibb Signs $11B Deal With BioNTech for Bispecific Cancer Antibody BNT327, Surpassing Recent Merck and Pfizer Moves

on